menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A New Hope for Patients with MS – The First FDA-Approved Biosimilar  

ReachMD Healthcare Image
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    This new disease-modifying treatment provides a more affordable option for patients with relapsing forms of MS, thus increasing the accessibility for patients with relapsing forms of MS and Crohn’s disease. Read more about the safety and efficacy of natalizumab-sztn from the recent clinical trial.

Facebook Comments

Recommended
Details
Comments
  • Overview

    This new disease-modifying treatment provides a more affordable option for patients with relapsing forms of MS, thus increasing the accessibility for patients with relapsing forms of MS and Crohn’s disease. Read more about the safety and efficacy of natalizumab-sztn from the recent clinical trial.

Facebook Comments

Schedule3 Oct 2023